Immunological Characteristics of COVID-19 Patients
- Conditions
- Covid19
- Registration Number
- NCT04679428
- Lead Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik
- Brief Summary
The study will look at the immunological characteristics of COVID-19 patients and determine neutralizing antibodies against SARS-CoV-2 virus.
- Detailed Description
The immunogram (quantitative TBNK immunophenotipisation) will be performed by flow cytometry, the antibody response will be determined by IVD ELISa.
Clinical biochemical and immunochemical (ECLIA) tests (including IL-6) will be performed on Cobas analyzers. Hemogram with differential blood picture will be performed with a hematology analyzer Sysmex XN 3100, examination of blood smears with CellaVision system or. microscope. Coagulation tests will be performed on BCS XP analyzers.
An in-house system for the analysis of SARS-CoV-2 virus fusion inhibitors on human cells will be used to detect the ability of antibodies from patients' serum to neutralize the virus and thus potential protection against re-infection. The system is quantitative, meaning that the titer of such antibodies could be determined, and thus the potential level of protection would be evaluated.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 230
Provide written consent before being included in the essay.
Positive cases of COVID-19 (based on polymerase chain reaction or positive antigen test for SARS-CoV-2).
Patients who are unable to give consent or who are unable to follow up will be excluded.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunological changes during and after COVID-19 infection July 2022 Correlation between TBNK dynamic and increase of neutralising antibodies
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Clinic of Respiratory and Allergic Diseases Golnik
🇸🇮Golnik, Slovenia